Gordon, Mark Forrest

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis

Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 1,610

Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., et al. (2015) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 151

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study

ten Kate, M., Redolfi, A., Peira, E., Bos, I., Vos, S. J., Vandenberghe, R., Gabel, S., Schaeverbeke, J., Scheltens, P., Blin, O., et al. (2018) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 78

The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson’s disease

Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 46